Payment overview · 2025
General Payments
$699.42
28 reported records · 14 companies
Healthcare provider profile · identity verified
Scott L Ray, DO
Allopathic & Osteopathic Physicians|Family Medicine · CLEARWATER, FL · NPI 1730187782
Verified facts
What the public records show
CMS Open Payments records show Scott L Ray, DO received $699.42 in general payments during 2025 across 28 reported records.
ABBVIE INC. accounted for 32.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Paxlovid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 141 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 148 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 1027 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Paxlovid by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $229.58 | 32.8% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $81.01 | 11.6% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $57.72 | 8.2% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $45.86 | 6.6% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $39.87 | 5.7% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $37.72 | 5.4% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $35.36 | 5.1% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $34.66 | 5.0% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $26.86 | 3.8% | 1 | 2025 |
| Cipher Pharmaceuticals US LLC | Unresolved — no canonical attribution shown | $25.50 | 3.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $24.95 | 3.6% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $21.67 | 3.1% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $21.26 | 3.0% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $17.40 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $699.42 | 28 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $192.23 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $57.72 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $45.86 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $42.92 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $42.92 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $37.72 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $37.52 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $35.36 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $34.66 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $26.86 | 1 | 2025 |
Source payment records
|
|||||
| Natroba Normalized: natroba |
Drug | Cipher Pharmaceuticals US LLC | $25.50 | 1 | 2025 |
Source payment records
|
|||||
| Spinosad Normalized: spinosad |
Drug | Cipher Pharmaceuticals US LLC | $25.50 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $24.95 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $22.35 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $21.67 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $21.26 | 1 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $19.47 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $17.88 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.88 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $17.76 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 63 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 32 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 141 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
22 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
66 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
55 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
52 | 49 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
141 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
148 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
63 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1027 | 125 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
32 | 29 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1320 | 253 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1193 | 260 |
| Eliquis | Apixaban | 1027 | 125 |
| Amlodipine Besylate | Amlodipine Besylate | 854 | 188 |
| Gabapentin | Gabapentin | 787 | 146 |
| Potassium Chloride | Potassium Chloride | 644 | 138 |
| Furosemide | Furosemide | 628 | 142 |
| Losartan Potassium | Losartan Potassium | 561 | 128 |
| Tamsulosin Hcl | Tamsulosin Hcl | 540 | 127 |
| Trazodone Hcl | Trazodone Hcl | 532 | 114 |
| Lisinopril | Lisinopril | 517 | 129 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 467 | 120 |
| Metoprolol Tartrate | Metoprolol Tartrate | 452 | 100 |
| Pantoprazole Sodium | Pantoprazole Sodium | 443 | 125 |
| Clopidogrel | Clopidogrel Bisulfate | 438 | 85 |
| Omeprazole | Omeprazole | 402 | 121 |
| Metoprolol Succinate | Metoprolol Succinate | 387 | 93 |
| Metformin Hcl | Metformin Hcl | 362 | 89 |
| Mirtazapine | Mirtazapine | 358 | 89 |
| Carvedilol | Carvedilol | 322 | 75 |
| Memantine Hcl | Memantine Hcl | 300 | 59 |
| Simvastatin | Simvastatin | 294 | 65 |
| Sertraline Hcl | Sertraline Hcl | 287 | 64 |
| Donepezil Hcl | Donepezil Hcl | 281 | 60 |
| Alprazolam | Alprazolam | 276 | 55 |
| Bumetanide | Bumetanide | 273 | 53 |
| Famotidine | Famotidine | 259 | 62 |
| Escitalopram Oxalate | Escitalopram Oxalate | 250 | 59 |
| Divalproex Sodium | Divalproex Sodium | 243 | 46 |
| Spironolactone | Spironolactone | 243 | 54 |
| Duloxetine Hcl | Duloxetine Hcl | 232 | 42 |
| Tramadol Hcl | Tramadol Hcl | 230 | 56 |
| Xarelto | Rivaroxaban | 227 | 37 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 209 | 53 |
| Montelukast Sodium | Montelukast Sodium | 209 | 48 |
| Prednisone | Prednisone | 206 | 63 |
| Finasteride | Finasteride | 198 | 41 |
| Latanoprost | Latanoprost | 194 | 40 |
| Levetiracetam | Levetiracetam | 194 | 31 |
| Alendronate Sodium | Alendronate Sodium | 181 | 41 |
| Allopurinol | Allopurinol | 172 | 46 |
| Pravastatin Sodium | Pravastatin Sodium | 163 | 39 |
| Baclofen | Baclofen | 161 | 21 |
| Ondansetron Hcl | Ondansetron Hcl | 152 | 65 |
| Januvia | Sitagliptin Phosphate | 150 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 150 | 38 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 148 | 26 |
| Jardiance | Empagliflozin | 148 | 28 |
| Celecoxib | Celecoxib | 144 | 44 |
| Lactulose | Lactulose | 142 | 23 |
| Buspirone Hcl | Buspirone Hcl | 141 | 44 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 141 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 140 | 44 |
| Atenolol | Atenolol | 135 | 26 |
| Amiodarone Hcl | Amiodarone Hcl | 126 | 24 |
| Lorazepam | Lorazepam | 126 | 43 |
| Citalopram Hbr | Citalopram Hydrobromide | 117 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 117 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 112 | 56 |
| Fluticasone Propionate | Fluticasone Propionate | 110 | 42 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 107 | 73 |
| Fluoxetine Hcl | Fluoxetine Hcl | 107 | 23 |
| Midodrine Hcl | Midodrine Hcl | 106 | 30 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 104 | 22 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 101 | 17 |
| Meloxicam | Meloxicam | 94 | 28 |
| Ropinirole Hcl | Ropinirole Hcl | 91 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 91 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 89 | 28 |
| Myrbetriq | Mirabegron | 88 | 17 |
| Ezetimibe | Ezetimibe | 87 | 23 |
| Warfarin Sodium | Warfarin Sodium | 85 | 16 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 84 | 12 |
| Nifedipine Er | Nifedipine | 84 | 20 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 84 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 83 | 16 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 82 | 47 |
| Calcitriol | Calcitriol | 80 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 80 | 18 |
| Brimonidine Tartrate | Brimonidine Tartrate | 77 | 16 |
| Cephalexin | Cephalexin | 76 | 43 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 74 | 33 |
| Diclofenac Sodium | Diclofenac Sodium | 73 | 22 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 71 | 14 |
| Methenamine Hippurate | Methenamine Hippurate | 70 | 11 |
| Olanzapine | Olanzapine | 69 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 68 | 47 |
| Methylprednisolone | Methylprednisolone | 67 | 54 |
| Farxiga | Dapagliflozin Propanediol | 66 | 13 |
| Glimepiride | Glimepiride | 63 | 23 |
| Nystatin | Nystatin | 63 | 40 |
| Ozempic | Semaglutide | 63 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 62 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 61 | 30 |
| Propranolol Hcl | Propranolol Hcl | 61 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 61 | 13 |
| Bupropion Xl | Bupropion Hcl | 59 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 59 | 15 |
| Solifenacin Succinate | Solifenacin Succinate | 59 | 13 |
| Topiramate | Topiramate | 58 | 11 |
| Risperidone | Risperidone | 57 | 18 |
| Oxcarbazepine | Oxcarbazepine | 56 | suppressed |
| Pregabalin | Pregabalin | 56 | 16 |
| Clonazepam | Clonazepam | 55 | 11 |
| Sucralfate | Sucralfate | 55 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 55 | 13 |
| Azithromycin | Azithromycin | 54 | 45 |
| Bupropion Hcl Sr | Bupropion Hcl | 54 | 14 |
| Entresto | Sacubitril/Valsartan | 54 | suppressed |
| Temazepam | Temazepam | 54 | suppressed |
| Trulicity | Dulaglutide | 54 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 53 | 12 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 52 | 49 |
| Gemfibrozil | Gemfibrozil | 52 | suppressed |
| Ibuprofen | Ibuprofen | 52 | 11 |
| Lovastatin | Lovastatin | 52 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 51 | 38 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 49 | suppressed |
| Lubiprostone | Lubiprostone | 49 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 48 | 15 |
| Ertapenem | Ertapenem Sodium | 45 | 27 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 45 | 28 |
| Santyl | Collagenase Clostridium Hist. | 44 | 23 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 43 | 12 |
| Glipizide | Glipizide | 43 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 42 | 27 |
| Clonidine Hcl | Clonidine Hcl | 42 | 20 |
| Diltiazem Hcl | Diltiazem Hcl | 42 | suppressed |
| Ketoconazole | Ketoconazole | 42 | 24 |
| Mupirocin | Mupirocin | 42 | 30 |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 41 | suppressed |
| Levofloxacin | Levofloxacin | 41 | 30 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 40 | 34 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 40 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 40 | suppressed |
| Valsartan | Valsartan | 40 | suppressed |
| Amoxicillin | Amoxicillin | 39 | 25 |
| Aripiprazole | Aripiprazole | 39 | 13 |
| Lidocaine | Lidocaine | 39 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 39 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 38 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 37 | suppressed |
| Cefdinir | Cefdinir | 36 | 18 |
| Propranolol Hcl Er | Propranolol Hcl | 36 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 36 | 13 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 36 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 35 | suppressed |
| Synthroid | Levothyroxine Sodium | 35 | suppressed |
| Timolol Maleate | Timolol Maleate | 35 | suppressed |
| Primidone | Primidone | 34 | suppressed |
| Brilinta | Ticagrelor | 33 | suppressed |
| Hydrocortisone | Hydrocortisone | 33 | 11 |
| Retacrit | Epoetin Alfa-Epbx | 33 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 32 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 32 | 29 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 32 | suppressed |
| Sotalol | Sotalol Hcl | 32 | suppressed |
| Folic Acid | Folic Acid | 31 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 31 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 31 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 31 | 20 |
| Breyna | Budesonide/Formoterol Fumarate | 30 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 30 | 11 |
| Loperamide | Loperamide Hcl | 30 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 30 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 29 | suppressed |
| Klor-Con 10 | Potassium Chloride | 29 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 29 | 13 |
| Novolog Flexpen | Insulin Aspart | 29 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 28 | 17 |
| Lamotrigine | Lamotrigine | 28 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl/Pf | 28 | 26 |
| Fenofibrate | Fenofibrate | 27 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 27 | suppressed |
| Tradjenta | Linagliptin | 27 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 26 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | suppressed |
| Rhopressa | Netarsudil Mesylate | 26 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 26 | suppressed |
| Diazepam | Diazepam | 25 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 25 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 25 | 11 |
| Methotrexate | Methotrexate Sodium | 25 | suppressed |
| Movantik | Naloxegol Oxalate | 25 | suppressed |
| Budesonide | Budesonide | 24 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 24 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 24 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 24 | 19 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 23 | suppressed |
| Insulin Lispro | Insulin Lispro | 23 | suppressed |
| Modafinil | Modafinil | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | suppressed |
| Carbamazepine Er | Carbamazepine | 22 | suppressed |
| Dexamethasone | Dexamethasone | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | 18 |
| Prolia | Denosumab | 22 | 14 |
| Propafenone Hcl | Propafenone Hcl | 22 | suppressed |
| Verapamil Er | Verapamil Hcl | 22 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 21 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 20 | 11 |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | 14 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Methocarbamol | Methocarbamol | 20 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 20 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Anastrozole | Anastrozole | 19 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Ssd | Silver Sulfadiazine | 19 | suppressed |
| Telmisartan | Telmisartan | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 18 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 17 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 17 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Clonidine | Clonidine | 16 | suppressed |
| Dorzolamide-Timolol | Dorzolamide/Timolol/Pf | 16 | suppressed |
| Haloperidol | Haloperidol | 16 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | 14 |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Procrit | Epoetin Alfa | 16 | suppressed |
| Acetic Acid | Acetic Acid | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Dalfampridine Er | Dalfampridine | 15 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 15 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 15 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 14 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 14 | 11 |
| Dapagliflozin | Dapagliflozin Propanediol | 14 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 14 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Erythromycin | Erythromycin Base | 13 | suppressed |
| Klor-Con 8 | Potassium Chloride | 13 | suppressed |
| Leflunomide | Leflunomide | 13 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 13 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 13 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 13 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Cartia Xt | Diltiazem Hcl | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Gemtesa | Vibegron | 12 | suppressed |
| Glucagon Emergency Kit | Glucagon | 12 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Lumigan | Bimatoprost | 12 | suppressed |
| Permethrin | Permethrin | 12 | suppressed |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Triamterene | Triamterene | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Enulose | Lactulose | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Formoterol Fumarate | Formoterol Fumarate | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Minoxidil | Minoxidil | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Restasis | Cyclosporine | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
| Verapamil Sr | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $699.42 · 28 records | ABBVIE INC. | AIRSUPRA, Cologuard Collection Kit, EVENITY, FREESTYLE LIBRE 3, KISUNLA, Leqembi, MOUNJARO, Natroba, Ozempic, PAXLOVID, QULIPTA, REXULTI, Rybelsus, Spinosad, TRELEGY ELLIPTA, TZIELD, UBRELVY, VRAYLAR, VYALEV, XIFAXAN, ZEPBOUND | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error